法國ERYtech Pharma
法國ERYtech制藥公司(ERYtech Pharma)創立于2004年11月,皮埃爾?奧利維爾?瓜諾先生(Pierre-Olivier Goineau)是公司董事會主席及聯合創始人。
ERYTECH醫藥SA是法國后期階段的生物制藥公司發展為腫瘤的藥用產品。該公司的專利核心技術的基礎上使用,以改善人體紅血細胞(紅細胞)的藥代動力學(PK)和藥效學(PD)的治療酶的特性(如天門冬酰胺酶)。
ERYTECH的主導產品,GRASPA?用于治療急性淋巴細胞白血?。ˋLL)
ERYTECH Pharma creates high value products for hospital market, mainly in oncology, hematology and immunology fields.
Headquartered in France (Lyon) with a cGMP manufacturing unit, ERYTECH Pharma has a US Office and a US location for cGMP clinical batches production at the American Red Cross.
ERYTECH Pharma’s business & revenue model is both:
An integrated business & revenue model for proprietary product to maximize value creation
A business development revenue model based on its R&D platform and partnership